Triveni Bio Inc.

About Triveni Bio Inc.

Triveni Bio is a clinical-stage biotech company focused on developing first-in-class therapeutics for immune and inflammatory diseases using a genetics-informed approach and advanced antibody engineering to transform treatment paradigms.

Products & Services

TRIV-509:A therapeutic in a Global Phase 2 Proof of Concept Study for Atopic Dermatitis, targeting the root cause of the disease with novel biology.

Pipeline Therapeutics:A range of therapeutics in development for immune and inflammatory diseases, leveraging genetics and antibody engineering.

Specialties

Genetics-informed therapeutic development Advanced antibody engineering Immune and inflammatory disease treatments Novel biology in atopic dermatitis

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series B T: - FT: Series B	A: 115000000 MR: - FA: 115 million FAN: 115000000	D: 2024-10-02 FD: 2024-10-02	8 investors

Series B Latest

2024-10-02

$115.0M

8 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

V

Vishal Patel

Chief Executive Officer

B

Bhaskar Srivastava

Chief Medical Officer

J

Jennifer Dovey

Chief Scientific Officer

N

Nicholas Scarchilli

Chief Operating Officer

S

Susan Wu

Head of Development Operations and Program Management

E

Eva Asp

Head of Biology

View 25 more team members with Pro

Unlock Full Team Directory

Recent News

Triveni Bio Inc. Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised